Does Depakote Increase Clozapine Levels?
No, valproic acid (Depakote) does not increase clozapine plasma concentrations—in fact, it appears to decrease them, particularly in smokers, while simultaneously reducing norclozapine (the major metabolite) levels through complex metabolic interactions.
The Pharmacokinetic Interaction
The interaction between valproic acid and clozapine is more nuanced than a simple increase or decrease in levels:
Valproic acid acts as a metabolic inducer of clozapine, not an inhibitor. Multiple studies demonstrate that VPA co-administration results in:
- 27-40% lower clozapine plasma concentrations after controlling for confounding variables 1, 2
- 40-45% reduction in norclozapine (N-desmethylclozapine) levels 1, 3, 4
- Significantly elevated clozapine-to-norclozapine ratios 4, 5
The mechanism involves VPA inducing clozapine 5N-glucuronide formation (a 250% increase), which diverts clozapine metabolism away from the N-desmethylation pathway 4. This explains why both parent drug and major metabolite levels decrease.
Critical Smoking Interaction
The effect of valproic acid on clozapine metabolism is substantially modified by smoking status:
- In non-smokers: VPA may cause mild inhibition (16% increase in clozapine levels) 1
- In smokers: VPA causes marked induction (22% decrease in clozapine levels, with smoking itself causing an additional 46% decrease when combined with VPA) 1
This interaction is clinically significant—one study found that the combination of smoking and concurrent VPA use increased relapse risk 5-fold (aHR 5.32) compared to non-VPA users 6.
Clinical Implications and Monitoring
When combining clozapine with valproic acid, you should:
- Anticipate lower clozapine levels, particularly in smokers—not higher levels requiring dose reduction
- Monitor clozapine plasma concentrations closely, targeting therapeutic range of 350-600 ng/mL 7, 8
- Consider dose increases of clozapine when adding VPA, using a dose-correction factor of approximately 1.3 in smokers 1
- Be vigilant for increased toxicity risk: Despite lower clozapine levels, VPA increases formation of toxic cysteinyl conjugates (CLZ-Cys) by 1.5-fold and CLZ-N-oxide cysteinyl conjugates by 2.1-fold, which may explain increased granulocyte toxicity 9
Important Caveats
The FDA clozapine label does not specifically address VPA interactions 10, though it notes that CYP1A2 and CYP3A4 inducers can decrease clozapine concentrations. The label does warn against concurrent use of medications that lower blood cell counts, stating "the use of concurrent medications that also have the potential to lower blood cell counts (e.g., carbamazepine) should be avoided" 11.
UGT2B10 genetic polymorphisms may further modify this interaction—patients with the GT genotype show even lower norclozapine levels and higher CLZ/NCLZ ratios when taking VPA 5.
Practical Algorithm
When prescribing VPA with clozapine:
- Measure baseline clozapine levels before adding VPA
- Recheck levels 2-4 weeks after VPA initiation
- If clozapine levels drop below 350 ng/mL: Increase clozapine dose by 20-30%
- Monitor for neutropenia more closely given increased toxic metabolite formation 9
- In smokers: Anticipate need for higher clozapine doses and counsel on smoking cessation
- Consider alternative mood stabilizers (lamotrigine, lithium) if clozapine levels become difficult to maintain
The traditional teaching that VPA increases clozapine levels is incorrect based on current evidence—the opposite is true in most clinical scenarios.